We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Acro Biotech Highlights Expanded Toxicology and Rapid Diagnostic Portfolio

By LabMedica International staff writers
Posted on 18 Nov 2025

Acro Biotech is presenting its extensive product range at MEDICA 2025 that includes approved drugs of abuse tests, women’s health related rapid tests, cardiac markers, tumor markers, among others.

Exhibiting at booth C40-5 in Hall 3, the company invites attendees to explore a portfolio spanning drugs of abuse (DOA) testing, fluorescence immunoassay (FIA) panels, and urine analysis. More...

On display are new DOA rapid tests for Scopolamine (SCOP), Citalopram (CIT), and Fentanyl (FYL), reflecting demand for broader toxicology coverage in hospital and occupational health workflows.

For laboratory medicine applications, the company’s booth features FIA tests covering cardiac and endocrine markers, including Troponin I/Myoglobin/CK‑MB (creatine kinase‑MB), Prolactin, and Vitamin D. Instrumentation on display includes the Apoti Plus Fluorescence Immunoassay Analyzer (1 Channel) for benchtop use, the AcrMove Up Handheld Fluorescence Immunoassay Analyzer for mobile testing, and the Optilyte Plus Urine Analyzer to support routine urinalysis.

The lineup also includes the Urine Cup for Multi‑Drug Testing aimed at streamlined specimen collection and rapid screening. At the company's booth, specialists will provide live demonstrations and discuss implementation to align with laboratory and near‑patient workflows across emergency care, toxicology, and chronic disease monitoring.

Related Links:
Acro Biotech


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Legionella Test
SOFIA Legionella FIA)
New
Liver Cancer Surveillance Test
EvoLiver
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.